Skip to content

The Study of Intermittent Theta Pulse Stimulation on Post-Stroke Attention Disorder

The Study of Intermittent Theta Pulse Stimulation on Post-Stroke Attention Disorder

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068669
Enrollment
Unknown
Registered
2023-02-27
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-Stroke Attention Disorder

Interventions

iTBS group:Intermittent theta pulse stimulation (iTBS)
Control group:sham-iTBS

Sponsors

Department of Rehabilitation Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) first stroke meeting the diagnostic criteria established by the Fourth National Cerebrovascular Disease Academic Conference in 1995 confirmed by MRI or CT. (2) stabilized vital signs and neurological symptoms, course of stroke between 2 weeks and 6 months. (3) age 30–80 years old, right-handed. (4) mild or moderate cognitive impairment, defined by Montreal Cognitive Assessment (MOCA) score =10 and < 26, with evidence of attention deficit initially screened by MOCA (attention function score = 4 ) and digit span test (digits forwards/backwards < 5). (5) patients can cooperate to complete the scale assessment without mental illness or communication barriers. (6) sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) patients with brain diseases other than cerebrovascular diseases, such as brain trauma, encephalitis, brain tumors, etc. (2) cognitive impairment that occurred before stroke or caused by Alzheimer's disease, Parkinson’s disease, dementia with Lewy bodies, etc. (3) history of substance or alcohol abuse, premorbid seizures, or neuropsychiatric diseases. (4) contraindications involving TMS and MRS (e.g., skull defect or skin damage at the stimulation site, intracranial implants, cardiac pacemakers, implanted drug pumps, etc). (5) serious impairments of the heart, lung, liver, kidney, and other organs, cannot tolerate training. (6) unable to cooperate with assessment and treatment due to severe visual, hearing, or speech impairment; (7) patients who had received TMS treatment or are currently participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Overall cognition; Attention Span;

Secondary

MeasureTime frame
selective attention, sustained attention, divided attention, shifting attention;Electrophysiological Assessment;Imaging evaluation;

Countries

China

Contacts

Public ContactLu Min

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

lumin@hust.edu.cn+86 139 7126 8939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 13, 2026